317 related articles for article (PubMed ID: 35111663)
21. Emerging CRISPR/Cas9 applications for T-cell gene editing.
Preece R; Georgiadis C
Emerg Top Life Sci; 2019 May; 3(3):261-275. PubMed ID: 33523139
[TBL] [Abstract][Full Text] [Related]
22. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology.
Tao R; Han X; Bai X; Yu J; Ma Y; Chen W; Zhang D; Li Z
Front Immunol; 2024; 15():1354825. PubMed ID: 38449862
[TBL] [Abstract][Full Text] [Related]
23. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy.
Li C; Mei H; Hu Y
Brief Funct Genomics; 2020 May; 19(3):175-182. PubMed ID: 31950135
[TBL] [Abstract][Full Text] [Related]
24. Advances in therapeutic application of CRISPR-Cas9.
Sun J; Wang J; Zheng D; Hu X
Brief Funct Genomics; 2020 May; 19(3):164-174. PubMed ID: 31769791
[TBL] [Abstract][Full Text] [Related]
25. CRISPR/Cas-based CAR-T cells: production and application.
Song P; Zhang Q; Xu Z; Shi Y; Jing R; Luo D
Biomark Res; 2024 May; 12(1):54. PubMed ID: 38816881
[TBL] [Abstract][Full Text] [Related]
26. CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell Therapy.
Park H; Kang YK; Shim G
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543240
[TBL] [Abstract][Full Text] [Related]
27. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
28. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.
Ghaffari S; Khalili N; Rezaei N
J Exp Clin Cancer Res; 2021 Aug; 40(1):269. PubMed ID: 34446084
[TBL] [Abstract][Full Text] [Related]
29. CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges.
Cheng X; Fan S; Wen C; Du X
Brief Funct Genomics; 2020 May; 19(3):209-214. PubMed ID: 32052006
[TBL] [Abstract][Full Text] [Related]
30. Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges.
Zhi L; Su X; Yin M; Zhang Z; Lu H; Niu Z; Guo C; Zhu W; Zhang X
Cell Immunol; 2021 Nov; 369():104436. PubMed ID: 34500148
[TBL] [Abstract][Full Text] [Related]
31. The implication of CRISPR/Cas9 genome editing technology in combating human oncoviruses.
Gilani U; Shaukat M; Rasheed A; Shahid M; Tasneem F; Arshad M; Rashid N; Shahzad N
J Med Virol; 2019 Jan; 91(1):1-13. PubMed ID: 30133783
[TBL] [Abstract][Full Text] [Related]
32. CRISPR technology for immuno-oncology applications.
Wang J; Balan V; Marincola F
Methods Enzymol; 2020; 635():251-266. PubMed ID: 32122549
[TBL] [Abstract][Full Text] [Related]
33. [The application of CRISPR/Cas9 genome editing technology in cancer research].
Wang DY; Ma N; Hui Y; Gao X
Yi Chuan; 2016 Jan; 38(1):1-8. PubMed ID: 26787518
[TBL] [Abstract][Full Text] [Related]
34. The CRISPR System and Cancer Immunotherapy Biomarkers.
Balan V; Wang J
Methods Mol Biol; 2020; 2055():301-322. PubMed ID: 31502158
[TBL] [Abstract][Full Text] [Related]
35. Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV.
Naeimi Kararoudi M; Likhite S; Elmas E; Yamamoto K; Schwartz M; Sorathia K; de Souza Fernandes Pereira M; Sezgin Y; Devine RD; Lyberger JM; Behbehani GK; Chakravarti N; Moriarity BS; Meyer K; Lee DA
Cell Rep Methods; 2022 Jun; 2(6):100236. PubMed ID: 35784645
[TBL] [Abstract][Full Text] [Related]
36. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy.
Potts MA; McDonald JA; Sutherland KD; Herold MJ
Eur J Immunol; 2020 Dec; 50(12):1871-1884. PubMed ID: 33202035
[TBL] [Abstract][Full Text] [Related]
37. Using CRISPR to enhance T cell effector function for therapeutic applications.
Freen-van Heeren JJ
Cytokine X; 2021 Mar; 3(1):100049. PubMed ID: 33604565
[TBL] [Abstract][Full Text] [Related]
38. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic gene editing in haematological disorders with CRISPR/Cas9.
Jensen TI; Axelgaard E; Bak RO
Br J Haematol; 2019 Jun; 185(5):821-835. PubMed ID: 30864164
[TBL] [Abstract][Full Text] [Related]
40. In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma.
Dubrot J; Lane-Reticker SK; Kessler EA; Ayer A; Mishra G; Wolfe CH; Zimmer MD; Du PP; Mahapatra A; Ockerman KM; Davis TGR; Kohnle IC; Pope HW; Allen PM; Olander KE; Iracheta-Vellve A; Doench JG; Haining WN; Yates KB; Manguso RT
Immunity; 2021 Mar; 54(3):571-585.e6. PubMed ID: 33497609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
